Phase II trial to assess the activity of ketoconazole and mitoxantrone plus GM-CSF [sargramostim] in patients with progressive hormone refractory prostate cancer
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Sargramostim (Primary) ; Ketoconazole; Mitoxantrone
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Aug 2008 Trial sponser changed from Berlex to Bayer as reported by ClinicalTrials.gov.
- 24 Aug 2008 Planned end date added (1 Sep 2008) as reported by ClinicalTrials.gov.